Premium
Polymorphisms in the androgen receptor and the prostate–specific antigen genes and prostate cancer risk
Author(s) -
Salinas Claudia A.,
Austin Melissa A.,
Ostrander Elaine O.,
Stanford Janet L.
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20230
Subject(s) - prostate cancer , androgen receptor , prostate specific antigen , odds ratio , medicine , prostate , oncology , population , androgen , genotype , endocrinology , cancer , biology , genetics , gene , hormone , environmental health
BACKGROUND Prostate cancer (PCa) is an androgen‐dependent disease. Polymorphic CAG and GGC microsatellites in the androgen receptor (AR) can alter transactivation of androgen‐responsive genes in in vitro studies. Potentially, this may influence PCa risk. METHODS Germline DNA samples and survey data were collected from 591 newly diagnosed PCa cases and 538 population‐based controls of similar age (40–64 years), from King County, WA. Odds ratios (ORs) and 95% confidence limits were estimated using logistic regression models. RESULTS No association was detected between PCa and having <22 versus ≥22 CAG repeats (OR = 1.1; 95% CI 0.9, 1.4) or ≤16 GGC versus >16 GGC repeats (OR = 1.0; 95% CI 0.9, 1.4). These findings were unchanged after controlling for body mass index or family history of PCa. No clear relation was detected between APS −158 G/A genotype and risk of PCa or serum prostate‐specific antigen (PSA) levels. These findings did not differ by stage or grade of PCa. CONCLUSIONS We found no evidence that risk of PCa is associated with the AR CAG, GGC, or PSA–158 AREI genetic polymorphisms in middle‐aged Caucasian men. © 2005 Wiley‐Liss, Inc.